Advertisement
Canada markets closed
  • S&P/TSX

    22,673.52
    +129.39 (+0.57%)
     
  • S&P 500

    5,615.35
    +30.81 (+0.55%)
     
  • DOW

    40,000.90
    +247.15 (+0.62%)
     
  • CAD/USD

    0.7334
    -0.0002 (-0.03%)
     
  • CRUDE OIL

    82.22
    -0.40 (-0.48%)
     
  • Bitcoin CAD

    78,511.45
    +54.98 (+0.07%)
     
  • CMC Crypto 200

    1,201.83
    +3.26 (+0.27%)
     
  • GOLD FUTURES

    2,416.40
    -5.50 (-0.23%)
     
  • RUSSELL 2000

    2,148.27
    +23.23 (+1.09%)
     
  • 10-Yr Bond

    4.1890
    -0.0040 (-0.10%)
     
  • NASDAQ

    18,398.45
    +115.04 (+0.63%)
     
  • VOLATILITY

    12.46
    -0.46 (-3.56%)
     
  • FTSE

    8,252.91
    +29.57 (+0.36%)
     
  • NIKKEI 225

    41,190.68
    -1,033.34 (-2.45%)
     
  • CAD/EUR

    0.6723
    -0.0024 (-0.36%)
     

Insulet CFO to step down, join 3M's healthcare business

The 3M Global Headquarters in Maplewood, Minnesota

(Reuters) -Insulet Corp said on Tuesday Wayde McMillan would step down as the medical device maker's chief financial officer, effective Oct. 20, to join 3M's healthcare business.

McMillan will join 3M as the financial chief of its unit, which the U.S. industrial conglomerate plans to spin off into a listed company.

3M expects to complete the planned spinoff, which it disclosed last year, by the end of 2023.

The unit focuses on wound care, oral care and healthcare technology.

Insulet on Tuesday also reaffirmed its annual forecast for sales of its insulin pumps and total revenue. The company in August had raised its revenue growth forecast to 22% to 25%, and outlook for total sales growth of its insulin delivery devices, Omnipod, to 25% to 28%.

ADVERTISEMENT

Insulet's accounting chief, Lauren Budden, will assume the additional responsibilities of interim CFO until a permanent successor is appointed, the medical device maker said.

Shares of Insulet were up 1.4% in extended trading.

(Reporting by Sriparna Roy in Bengaluru; Editing by Shilpi Majumdar and Maju Samuel)